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Abstract
Background: Opioid-substitution treatment (OST) for opioid dependence (OD) has proven effective in
retaining patients in treatment and reducing illegal opiate abuse and crime. Consequently, the World
Health Organization (WHO) has listed the opioid agonists methadone and buprenorphine as essential
drugs for OD that should be available worldwide. In many areas of the world, OD is often associated with
concomitant benzodiazepine (BZD) dependence and abuse, which complicates treatment. However,
possible changes in the cognitive functioning of these patients are not well-known. The present study is
the first to examine longitudinal stability of memory function in OST patients with BZD use, thus providing
a new tool for health policy authorities in evaluating the usefulness of OST.
Methods: Within the first two months (T1) and between 6–9 months (T2) after OST admission, we
followed the working memory, immediate verbal memory, and memory consolidation of 13 methadone-
and 15 buprenorphine- or buprenorphine/naloxone-treated patients with BZD dependence or abuse
disorder. The results were compared to those of fifteen normal comparison participants. All participants
also completed a self-reported memory complaint questionnaire on both occasions.
Results:  Both patient groups performed statistically significantly worse than normal comparison
participants in working memory at time points T1 and T2. In immediate verbal memory, as measured by
list learning at T1, patients scored lower than normal comparison participants. Both patient groups
reported significantly more subjective memory problems than normal comparison participants. Patients
with more memory complaints recalled fewer items at T2 from the verbal list they had learned at T1 than
those patients with fewer memory complaints. The significance of the main analyses remained nearly the
same when the statistical tests were performed without buprenorphine-only patients leaving 12 patients
to buprenorphine/naloxone group.
Conclusion: Working memory may be persistently affected in OST patients with BZD use. A high
number of memory complaints among OST patients with BZD use may indicate memory consolidation
impairment. These findings show that recovery of memory function in OD patients treated along with
BZDs takes time, and their memory complaints may have practical relevance.
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Introduction
Opioid-substitution treatment with the full mu opioid
receptor agonist methadone or the partial agonist
buprenorphine is the most effective treatment for OD
[1,2]. Follow-up studies of OST patients have shown con-
sistently high retention in OST, fewer crimes, reduction in
substance abuse, and improved health [3,4]. However, the
psychosocial recovery of OD patients during treatment is
still controversial. It has been stated that while opioid
abuse and other problem behavior reduces during the
OST, there is little research-based evidence for improve-
ment if patient-centered indicators of quality of life are
used [5]. While this critique underestimates the impor-
tance of reduction of the health hazards of OD, it also
shows the shortage studies using objective measures of
psychological functions. In order to meet this challenge,
studying memory function of OD patients is an important
element, because the patients often complain poor mem-
ory [6,7]. Therefore, in this longitudinal study memory
function of OST patients was evaluated by tests and sub-
jective memory questionnaire. Because in Finland most
OD patients are prescribed benzodiazepines or abuse
them from illegal sources [7,8], we examined memory
function of this clinically relevant majority.
Some studies have shown substantial memory deficits
among OD patients in methadone treatment even after
years of treatment [9,10]. Also, buprenorphine-treated
patients may show poor memory function [11,12]. How-
ever, only two studies have examined the longitudinal sta-
bility of memory function during OST. In the seminal
longitudinal study by Grevert et al., the memory perform-
ance of OST patients, of whom about one third tested pos-
itive for other drugs of abuse during the tests, was assessed
three times within the first three months of treatment
[13]. No baseline or subsequent differences between the
methadone patients and a comparison group were seen in
objective or subjective memory function. No significant
correlations were seen between drug screen status and
memory test results. However, as the patients performed
the tests immediately before or after the methadone dose,
that is, when their plasma concentration is known to be at
the lowest level, short-term negative effects of high meth-
adone concentrations may have been missed. In a more
recent study by Gruber et al., the tests were done a few
hours after the methadone dose [14]. The patients' mem-
ory performance was tested first within the first few weeks
of OST and again after two months of treatment.
Although 65% of the patients tested positive for any illicit
use at the first test and 76% at the second test, the results
showed a statistically significant improvement in verbal
list learning among patients.
In our previous study, we found that both methadone-
and buprenorphine/naloxone-treated patients in early
OST performed worse than normal comparison partici-
pants on a working memory task [15]. The verbal memory
deficit was more pronounced in methadone-treated
patients than in buprenorphine/naloxone-treated
patients. Although the results partially favored buprenor-
phine/naloxone-treated patients, BZD co-medication that
was common in both patient groups, may have affected
the results. There are no longitudinal studies comparing
the effects of OST drugs while patients use BZDs. How-
ever, there is some evidence for acute negative effects of
opioid agonists on working memory in drug-naïve
healthy volunteers and for chronic negative effects in pain
patients [16,17]. The negative effects of BZDs on working
memory and long-term memory are better – known, vary
from small to moderate, and may last several months after
cessation of use [18]. Of special interest is the study of
Lintzeris et al., which found that in comparison to a pla-
cebo condition, methadone dose alone, or buprenor-
phine dose in combination with BZD diazepam impairs
verbal recall in OST patients [19]. Given these findings
suggesting memory deficits in OST patients using BZDs,
we did a follow-up study of memory function in OD
patients treated with methadone or buprenorphine
(including buprenorphine/naloxone) along with BZDs.
In order to control for the effects of repeated testing, a
comparison group performed similar tests. Working
memory, immediate verbal memory, and memory con-
solidation were examined. The participants also com-
pleted the Memory Complaint Questionnaire, which
assesses subjective memory function [20].
We hypothesized that working memory function in both
OST patient groups treated along with BZDs would be
impaired relative to normal comparison participants in
the first testing (T1) and would not show improvement.
Second, we hypothesized that immediate verbal memory
would be impaired relative to normal comparison partic-
ipants at T1 and would not show improvement in OST
patients also using BZDs. Third, we hypothesized that
memory consolidation would be impaired in OST
patients. Finally, we hypothesized that among OST
patients subjective and objective memory function would
correlate negatively.
Methods
The study participants with OD were volunteers admitted
for standard OST in the addiction clinics of the Helsinki
area. Normal comparison participants were recruited
from adult education centers and by word of mouth. All
participants included in the study were between 18 – 50
years of age and native Finnish speakers. For OST patients,
additional inclusion criteria were OD diagnosis, BZD
dependence or abuse diagnosis, start of OST during the
last two months, and treatment of OD with methadone,
buprenorphine, or buprenorphine/naloxone. We
excluded participants with uncontrolled polysubstance
abuse, acute alcohol abuse, or acute axis I psychiatric mor-Substance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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bidity other than substance abuse related. We also
excluded participants with severe brain injury, chronic
neurological disease, history of other than substance-
induced psychoses, epileptic seizures, human immunode-
ficiency virus (HIV) infection, pregnancy, or primary cog-
nitive deficit. For these purposes, psychiatric interviews by
clinical psychiatrist were conducted for all participants,
and diagnostic criteria from the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) were applied
[21,22].
Each OST participant eligible for our study was screened
by urine sample for substance abuse on the day of testing
and at least once in the preceding month. One third of
normal comparison participants were chosen at random
for screening for drug of abuse. Participants showing signs
of current intoxication, ongoing binge on any substance
of abuse, and those with any extra psychoactive drug dose
within 24 h were all excluded. According to these criteria
13 methadone- and 15 buprenorphine/naloxone- or
buprenorphine-treated patients and 15 normal compari-
son participants could be studied twice. This represents
59% of volunteer methadone patients at T1, 52% of
buprenorphine patients (including both products), and
79% of normal comparison participants. Eight volunteer
patients were excluded from the study based on their sub-
stance abuse before the test. Fourteen eligible patients and
four normal comparison participants dropped out of the
study between T1 and T2. At T1, 23% of the methadone
patients and 40% of the buprenorphine patients were
tested in inpatient settings. At T2, none of the methadone
patients and 13% of the buprenorphine patients were
tested in inpatient settings.
Ethics
The study was approved by the independent Hospital Dis-
trict of Helsinki and Uusimaa Ethical Committee (permis-
sion 90/2001). The study was conducted in accordance
with the 1964 Declaration of Helsinki. All patients were
required to be able to read and understand the patient
information sheet and sign the informed consent form.
All participants were free to discontinue participation in
the study whenever they wanted. The participants were
reimbursed with € 40 if they attended all study visits.
Procedure
Cognitive testing was done three to six hours after admin-
istration of the opioid-substitution drug. During this time
the drug plasma concentration is at its peak [23]. At T1,
the methadone patients were given, under supervision on
the morning of the test day, a mean dose of 72.9 mg (SD
= 35.2) of liquid methadone, range 35 – 150 mg. At T2,
the respective values for methadone were 125.7 mg (SD =
35.8), range 70 – 180 mg. At T1, the buprenorphine
patients were given, under supervision on the morning of
the test day, a mean dose of 17.3 mg (SD = 3.6) of sublin-
gual buprenorphine, range 12 – 24 mg. At T2, the respec-
tive values were 22.7 mg (SD = 2.9), range 16 – 28 mg.
Rise of the dose was statistically significant in both groups
(Wilcoxon's Signed Ranks test, exact (2-sided) p = 0.001 in
both groups). In the buprenorphine group, 80% of the
patients were given buprenorphine/naloxone; thus, they
were also given sublingual naloxone in a ratio of 1:4
together with their buprenorphine dose. Several studies
have shown that among OD individuals sublingual
naloxone has minimal if any interference with the opioid
agonist effects of the buprenorphine [24-26]. Other pre-
scribed psychoactive medications were given to the
patients according to their clinical dose regimen. Table 1
describes the BZDs and their doses used within the 24-
hour period before the tests. In order to compare the BZD
doses of the groups, all BZDs were converted to diazepam
equivalent doses according to their known clinical
potency [27]. Temazepam and midazolam doses were
halved in order to account for their use as hypnotics on
the night before testing. After this conversion, no statisti-
cally significant difference existed between the patient
groups in their mean estimated diazepam equivalent dose
at T1 or T2. There was no significant change between the
T1 and T2 BZD doses within the groups. The diazepam
equivalent dose at T1 was on average 26.2 mg (SD = 18.5)
in the methadone group and at T2 26.5 (SD = 10.0); in the
buprenorphine group, the respective values were 27.7 (SD
= 24.1) and 21.0 (SD = 11.1). In other types of psychoac-
tive drugs there were no statistically significant changes
between the test points.
Memory tests
Working memory refers to the limited capacity short-
term store that temporarily maintains information, which
is lost without rehearsal [28]. It was assessed by the Letter-
Number-Sequencing task from the Wechsler Memory
Scale-third version (WMS-III) and by the computerized
version of the Paced Auditory Serial Addition Task
(PASAT) from the FORAMENRehab software package [29-
31].
Immediate verbal memory refers to immediate storage of
verbally presented items in those situations that exceed
the capacity of sensory-specific working memory stores.
Typical examples of immediate verbal memory measures
include recall of a list or story. Immediate verbal memory
is thought to rely on both working and long-term memory
stores. This concurrent activation of two memory stores
has recently been experimentally confirmed [32]. Imme-
diate verbal memory was assessed by two verbal memory
tasks, a list learning and a story recall task: the Memory for
Persons Data and The Logical Memory [29,33]. Both tasks
were presented in modified versions. The details of these
tasks are presented in our previous study [15].Substance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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Table 1: Co-medications among patients used within the last 24 h before testing at T1 and T2
Methadone (n = 13) Buprenorphine or Buprenorphine/Naloxone (n = 15)
Proportion of patients Dose, range Proportion of patients Dose, range
Antidepressants (any), T1/T2 54%/46% 40%/53%
Citalopram T1 8% 40 mg - -
Citalopram T2 - - 13% 10 mg
Escitalopram T1 8% 5 mg - -
Escitalopram T2 8% 10 mg - -
Doxepine T1 - - 13% 75 – 100 mg
Doxepine T2 8% 50 mg 20% 25 – 100 mg
Fluoxetine T1 15% 20 – 30 mg - -
Fluoxetine T2 8% 40 mg - -
Milnacipran T1 - - - -
Milnacipran T2 - - 7% 50 mg
Mirtazapine T1 25% 15 – 30 mg - -
Mirtazapine T2 25% 30 mg 7% 30 mg
Paroxetine T1 8% 50 mg 7% 50 mg
Paroxetine T2 - - 13% 40 mg
Sertraline T1 - - 7% 50 mg
Sertraline T2 - - 7% 50 mg
Trimipramine T1 - - - -
Trimipramine T2 8% 150 mg - -
Venlafaxine T1 - - 13% 75 mg
Venlafaxine T2 - - 7% 75 mg
Anxiolytics, sedatives and 
hypnotics: Benzodiazepines (any), 
T1/T2
87%/100% 93%/100%
Alpratzolam T1 - - 13% 1 – 2 mg
Alpratzolam T2 - - 13% 1 – 2 mg
Clonazepam T1 - - 13% 2 – 5 mg
Clonazepam T2 - - - -
Diazepam T1 46% 10 – 55 mg 47% 10 – 40 mg
Diazepam T2 38% 15 – 30 mg 67% 5 – 30 mg
Oxazepam T1 31% 60 – 120 mg 33% 30 – 90 mg
Oxazepam T2 46% 15 – 60 mg 20% 55 – 60 mg
MidazolamT1a -- - -
MidazolamT2a - - 7% 30 mg
Temazepam T1a 31% 20 mg 13% 20 mg
Temazepam T2a 15% 20 – 40 mg 13% 20 – 40 mgSubstance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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Memory consolidation refers to the storage and consoli-
dation of memory traces. Early memory consolidation
lasts from minutes to hours and late memory consolida-
tion from weeks to years; these rely partly on separate neu-
ral processes [34,35]. Early memory consolidation was
assessed by the percentage of the Logical Memory and
Memory for Persons Data items successfully recalled by
free recall after a short delay (30 min). Late memory con-
solidation was assessed by free recall of the Memory for
Persons Data items at T2, which occurred after at least four
and on average six, months after initial learning. Partici-
pants were further asked to rate the certainty of their
answers after the long delay. This may give additional
information about the memory processes the participants
are employing [36]. If the participant gave the right
answer, it was asked if he/she was certain that he/she actu-
ally remembered the answer or if he/she only felt he/she
knew the answer but was not certain about it. In the case
of "felt" or no answer, three nearly identical alternatives
were given, one of them being correct. After the partici-
pant gave his/her choice, he/she was asked if he/she
remembered, felt, or just guessed the answer.
Non-benzodiazepine hypnotics 
(any), T1/T2
15%/8% 20%/7%
Zolpidem T1a -- - -
Zolpidem T2a 8% 10 mg 7% 10 mg
Zopiclone T1a 15% 7.5 mg 20% 7.5 – 15 mg
Zopiclone T2a 8% 7.5 mg 7% 7.5 mg
Neuroleptics (any), T1/T2b 20%/8% 7%/7%
Levomepromazine T1 - - - -
Levomepromazine T2 8% 50 mg - -
Quetiapine T1 20% 50 – 300 mg 7% 300 mg
Quetiapine T2 - - 7% 150 mg
Rispiderone T1 - - - -
Rispiderone T2 8% - - -
Substance abuse withdrawal 
symptom or (non-opioid) pain 
relievers (any), T1/T2
42%/25% 40%/13%
Disulfiram T2 - - - -
Disulfiram T2 8% 600 mg - -
Hydroxyzine T1 25% 25 – 200 mg 27% 75 – 200 mg
Hydroxyzine T2 8% 50 mg 7% 100 mg
Ibuprofen T1 8% 600 mg 7% 400 mg
Ibuprofen T2 - - 7% 600 mg
Lofexidine T1 8% 0,2 mg 20% 0.2 – 0.6 mg
Lofexidine T2 - - - -
Metoclopramide T1 8% 10 mg - -
Metoclopramide T2 - - - -
Naproxen T1 8% 500 mg - -
Naproxen T2 - - - -
Propranol T1 8% 20 mg - -
Propranol T2 - - - -
Valproate T1 8% 1000 mg 20% 500 – 1000 mg
Valproate T2 - - 7% 100 mg
a Used as a hypnotic on the night before testing.
b Used for anxiolysis.
Table 1: Co-medications among patients used within the last 24 h before testing at T1 and T2 (Continued)Substance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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Subjective memory functioning was assessed by the Finn-
ish version of the Memory Complaint Questionnaire, the
MCQ [20]. In the MCQ, the participant is asked how his/
her memory now functions compared to when he/she was
younger. Several answers are given, using a Likert-type
scale, describing how well memory functions in everyday
tasks (remembering persons, things, news, shopping list
items, etc.). A high score indicates subjective memory
impairment.
Statistical Analysis
Overall group differences in memory performance at T1
and T2 were tested for statistical significance using multi-
ple planned analysis of covariance (ANCOVA) with years
of education and verbal IQ estimate as covariates.
Although there were no statistically significant differences
between the groups in the verbal IQ, it was used as a cov-
ariate because it is known to affect memory performance
in tasks with verbal content [37]. ANCOVA was followed,
when appropriate, by pairwise group comparisons using
normal comparison group as a reference group. The
Holm's sequential Bonferroni procedure was used to con-
trol for Type I error across the pairwise comparisons [38].
In all analyses, statistical significance was set at 0.05 (two-
tailed). In the Memory for Persons Data, the data were
highly skewed due to a ceiling effect in the initial learning
and recall at T1. At T2, the Memory for Persons Data for
delayed recall was skewed because of small variance.
Because of these violations of the assumptions of para-
metric testing, we analyzed these conditions by Kruskal-
Wallis ANOVAs, which were followed, when appropriate,
by pairwise Mann-Whitney U tests. In order to confirm
the validity of combining buprenorphine/naloxone and
buprenorphine-only patients, the ANCOVAs and ANO-
VAs were also performed with buprenorphine/naloxone
patients (n = 12). The cross-sectional MCQ scores and the
MCQ T2 differences between high vs. low score groups
were analyzed by t-tests or Mann-Whitney U tests. Corre-
lations between the MCQ values and cognitive variables
were analyzed by Pearson's product moment correlation
or Spearman's rho correlations depending on the normal-
ity of the variables. Correlations of at least .35 will be
reported. The statistical significance of correlations was
determined by using the Holm-Bonferroni procedure.
Longitudinal changes were analyzed by repeated meas-
ures ANCOVA using education and VIQ as a covariates
and the comparison group as a reference group. All statis-
tical analyses were performed using SPSS statistical soft-
ware, version 15.0, with the exception of the effect size
calculations. For this purpose, an effect size calculator
provided by Durham University, UK was employed
[39,40]; and the Cohen's d values were corrected by
Hedge's correction for small sample bias.
Results
Study demographics
Table 2 shows the comparisons of demographic variables
of each group. The group difference in verbal intelligence
(Verbal IQ) was statistically non-significant even though
the comparison group had more education than the
patient groups. There were no significant differences
between the OST groups in history of substance abuse,
duration of OST, or the prevalence of psychiatric co-mor-
bidity. Personality disorder diagnoses were common in
both patient groups. Buprenorphine was the main opioid
of abuse before the OST admission in both groups.
Among patients, no major change in the number of non-
opioid substances abused during the recent month before
the T1 or T2 testing was seen during the study period.
Group comparisons at T1
In Table 3, an overview of unadjusted memory test results
at both test points is presented together with statistical
comparisons for years of education and verbal IQ adjusted
values, whenever adjusting was possible. In working mem-
ory tests, the methadone patients were inferior to controls
in the PASAT, but in the Letter-Number Sequencing the
group difference remained non-significant. The buprenor-
phine patients were inferior to normal comparison partici-
pants on the both of the working memory tests. In
immediate verbal memory as measured by the first learning
trial of the Memory for Persons Data, both patient groups
performed significantly worse than normal comparison
group. In early memory consolidation as measured by
short-term retention of percentages of the Logical Memory
and the Memory for Persons Data items, no significant
group differences emerged. The statistical significance of
the analyses remained the same when the analyses outlined
in the Table 3 were done with buprenorphine/naloxone
patients (n = 12) instead of combining the buprenorphine-
only and buprenorphine/naloxone patients. Statistically
significant values of overall group effects were, in order, The
Letter-Number Sequencing, The PASAT, the first trial of the
Memory for Persons Data, and the MCQ (F (2, 35) = 3.63,
p = 0.009; F (2, 35) = 9.57, p < 0.001; Χ2 (2, N = 40) = 7.99,
exact p = 0.018; Χ2, (2, N = 40) = 11.83, exact p = 0.004).
After this, pairwise analyses between the buprenorphine/
naloxone and normal comparison groups were performed.
In the Letter-Number Sequencing the pairwise group com-
parison was statistically non-significant (t (26) = 2.67, p =
0.065). In the PASAT and in the first trial of the Memory
Persons Data, the buprenorphine/naloxone group showed
worse performance than the normal comparison group (t
(26) = 4.71, p = 0.00; Mann-Whitney U = 45.50, exact p =
0.028, respectively). In the MCQ, the buprenorphine/
naloxone patients reported more memory complaints than
the comparison participants (Mann-Whitney U = 26.00,
exact p = 0.004).Substance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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Table 2: Group demographics
Methadone
(n = 13)
Buprenorphine or 
Buprenorphine/Naloxone
(n = 15)
Normal Comparison
(n = 15)
Group comparison
p-valuesa
Age, mean of years at T1 (SD) 29.2 (6.8) 27.7 (6.8) 28.7 (9.6) M vs. BN, p = 0.99
M vs. NC, p = 0.99
BN vs. NC, p = 0.99
Sex: females/males 7/6 4/11 8/7 M vs. BN, p = 0.14
M vs. NC, p = 0.98
BN vs. NC, p = 0.14
Verbal intelligence, Meanb (SD) 100.6 (11.4) 99.4 (9.3) 104.1 (9.6) M vs. BN, p = 0.99
M vs. NC, p = 0.74
BN vs. NC, p = 0.63
Education, mean of years (SD) 10.1 (1.2) 10.5 (2.0) 12.6 (1.3) M vs. BN, p = 0.54
M < NC***, p < 0.001
BN < NC**, p = 0.006
Opioid of abuse used within last 
month at T1
Buprenorphine 85% 100% - M vs. BN, p = 0.48c
Heroin 15% 0%
Other substances of abuse used within 
last month at T1 and T2
Alcohol (heavy use)d 15%/15% 13%/7% 7%/7% M vs. BN vs. NC (T1/T2),
p = 0.99c/0.99c
Amphetamine 8%/8% 13%/7% - M vs. BN vs. NC (T1/T2)
p = 0.99c/0.99c
Benzodiazepine, any Use 100%/100% 100%/100% 0%/0% M & BN > NC*** (T1/T2),
p < 0.001c/p < 0.001c
Benzodiazepine, extra doses 38%/38% 42%/33% - M vs. BN (T1/T2),
p = 0.62/p = 0.78c
Cannabis 31%/31% 40%/27% - M vs. BN (T1/T2),
p = 0.83c/0.84c
Nicotine (daily use) 100%/100% 100%/100% 33%/33% M & BN > NC*** (T1/T2),
p < 0.001c/p < 0.001c
Duration of OST in the day of testing 
at T1, Mean of days (SD)
21 (14) 19 (12) - M vs. BN, p = 0.69
Duration of OST on the day of testing 
at T2, Mean of days (SD)
213 (25) 224 (17) - M vs. BN, p = 0.15
Participants with other dependence or 
abuse diagnosis at T1
Alcohol 0% 0% 0% M vs. BN vs. NC, p = 0.99c
Amphetamine 0% 0% - M vs. BN, p = 0.99c
Benzodiazepine 100% 100% - M vs. BN, p = 0.99c
Cannabis 15% 20% - M vs. BN, p = 0.99
Nicotine 100% 100% 33% M vs. BN, p = 0.99c
M vs. NC, p = 0.13c
BN vs. NC, p = 0.12c
Participants with any DSM-IV axis I 
diagnosis at T1
15% 20% 0% M vs. BN, p = 0.99c
M vs. NC, p = 0.21c
BN vs. NC, p = 0.22cSubstance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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Group comparisons at T2
At T2, both patient groups were inferior to normal com-
parison group in working memory tests. In immediate
verbal memory assessed by the immediate recall of the
Logical Memory items, no significant group differences
were seen. In early memory consolidation assessed by the
Logical Memory short-term retention percentage, group
differences were not significant. In late memory consoli-
dation assessed by the Memory for Persons Data free recall
or recognition retention percentages after at least four
months' delay, there were no group differences. Again,
dropping buprenorphine-only patients from the
buprenorphine group did not change the statistical signif-
icance of the overall ANOVAs or ANCOVAs. Significance
values of overall group effects were, in order, the Letter-
Number Sequencing, The PASAT, and the MCQ (F(2, 35)
= 3.82, p = 0.032, (F(2, 35) = 7.52, p = 0.02, (Χ2, (2, N =
40) = 15.91, exact p  < 0.001). Pairwise comparisons
between the buprenorphine/naloxone and normal com-
parison groups favored the comparison group in both
working memory tasks: the Letter-Number Sequencing
and The PASAT, respectively (t (26) = 2.21, p = 0.03; t (26)
= 3.33, p  = 0.002). In the MCQ, the buprenorphine/
naloxone patients reported more memory complaints the
normal comparison participants (Mann-Whitney U  =
29.50, exact p = 0.004).
Interestingly, total "black-outs" in long delay free recall
were rare. Only one methadone patient, two buprenor-
phine patients, and one comparison participant could not
recall any items from the Memory for Persons Data in this
condition. From Figure 1, which shows lines for cumula-
tive percentages, it can be seen that about 50% of the nor-
mal comparison participants and buprenorphine patients
could recall at least 4 items out of 15 correctly, while the
corresponding score was 2 items among the methadone
patients. When asked about the certainty of their answers,
the patients were non-significantly more certain than the
normal comparison participants that they actually
remembered, not just felt, the correct answers they gave.
On average, methadone-treated patients said that they
surely remembered a mean of 64.1% of their correct free
recall answers (SD = 38.8). In the buprenorphine group
the corresponding figure was 67.2% (SD = 24.1) and in
the normal comparison group 45.5% (SD = 31.3). In the
same vein, there were no significant group differences in
certainty of recognized correct answers (data not shown).
Both patient groups again reported significantly more
memory complaints in the MCQ.
Correlations between subjective and objective memory 
functions among the patients
The highest correlation between subjective MCQ score
and the objective memory tests completed by the OST
patients at T1 was – .38 for the Logical Memory retention
percent after short delay (30 min). However, after correc-
tion for multiple comparisons, this moderate correlation
was statistically non-significant. The correlation between
the MCQ score at T1 and the long delay free recall of the
Memory for Persons Data items at T2, that is, at least four
months after initial learning, was – .58 and statistically
significant, p = 0.028. This relationship is depicted in Fig-
ure 1. At T2, two moderate correlations between subjec-
tive MCQ score at T2 and objective memory performance
of the patients were seen: – .40 for long delay free recall of
the Memory for Persons Data items and – .39 for the
PASAT. However, after correction for multiple compari-
sons these were no longer statistically significant. In order
to explore how the OST patients with high MCQ scores at
the stabilized phase (T2) are different from those with low
MCQ scores, the patient group was divided into high vs.
low memory complaints groups using the T2 MCQ
median score as the cut-off. Patients with scores of 26 or
more at T2 made up the high memory complaints group
Participants with any personality 
disorder diagnosis (DSM-IV axis II) at 
T1
54% 59% 0% M vs. BN, p = 0.99c
M > NC**, p = 0.003c
BN > NC**, p = 0.002c
Duration of opioid abuse at T1, Mean 
of years (SD)
11.4 (5.5) 9.0 (2.9) - M vs. BN, p = 0.26
Duration of any substance abuse at 
T1, Mean of years (SD)
15.0 (5.1) 13.4 (5.2) - M vs. BN, p = 0.37
a Based on pairwise group comparisons with analysis of variance (ANOVA) or chi-squared test.
b Estimation based on the WAIS-R Vocabulary score.
c Fisher's Exact Test (2-tailed).
d Alcohol use was considered heavy if it was at least a mean of 16 portions weekly for females and 24 portions weekly for males. One portion was 
defined as 12 g of alcohol.
BN = buprenorphine or buprenorphine/naloxone, M = methadone, NC = Normal comparison.
*** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
Table 2: Group demographics (Continued)Substance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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Table 3: Group comparisons of memory functions at T1 and T2
Domain or Test Methadone
(n = 13)
Buprenorphine or 
Buprenorphine/
Naloxone
(n = 15)
Normal 
Comparison
(n = 15)
Group effect Statistical com-
parisons 
between normal 
comparison and 
patient groups 
using years of 
education and 
VIQ adjusted 
scores, when-
ever possibleb
Effect sizes, 
whenever 
possible
M (SD) M (SD) M (SD)
Working memory, 
raw scores
WMS-III Letter-Number 
Sequencing at T1
9.6 (2.3) 8.4 (2.3) 11.7 (3.2) F (2, 38) = 4.57
p = 0.017*
t(27) = 1..84, p = 
0.074, M vs. NC = 
ns
d = 0.68
t(29) = 3.02, p = 
0.008, NC > BN **
d = 1.01
WMS-III Letter-Number 
Sequencing at T2
8.6 (2.1) 9.2 (2.3) 11.6 (2.9) F (2, 38) = 4.19, 
p = 0.023*
t(27) = 2.76, p = 
0.018, NC > M*
d = 1.05
t (29) = 2.39, p = 
0.022, NC > BN *
d = 0.83
PASAT at T1 31.4 (9.2) 31.8 (10.7)a 46.7 (9.4) F (2, 38) = 9.84
p = 0.001***
t(27) = 4.19, p < 
0.001, NC > M ***
d = 1.43
PASAT at T2 31.6 (8.6) 34.1 (8.4) 46.0 (8.7)a F (2, 38) = 7.15 
p = 0.002**
t(29) = 3.70, p < 
0.001, NC > BN***
d = 1.54
t(27) = 3.47, p = 
0.002, NC > M**
d = 1.42
t(29) = 3.32, p = 
0.002, NC > BN**
d = 1.24
Immediate verbal 
memory, raw scores
Memory for Persons 
Data, first trial at T1
10.7 (2.6) 10.8 (2.5) 13.0 (1.5) χ2(2, N = 43) = 
8.91
p = 0.012*
U = 43.0, p = 0.011, 
NC > M*
-
U = 51.5, p = 0.020, 
NC > BN*
Memory for Persons 
Data, sum of last two 
trials (T1)
14.9 (0.2) 14.6 (0.7) 14.9 (0.2) χ2 (2, N = 43) = 
2.75
p = 0.25
- -
WMS-III Logical 
Memory, immediate free 
recall (T1)
12.9 (2.4) 15.1 (4.3) 16.3 (3.6) F (2, 38) = 1.90, 
p = 0.16
--
WMS-III Logical 
Memory, immediate free 
recall (T2)
14.2 (3.1) 14.1 (3.3) 16.3 (3.1) F (2, 38) = 1.25,
p = 0.30
--
Memory 
consolidation, 
percentages
WMS-III Logical 
Memory, free recall after 
short-delay (30 min) 
(T1)
91.4 (15.3) 91.7 (14.0) 87.5 (13.1) F (2, 38) = 0.64,
p = 0.94
--Substance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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(n = 14) and those with scores up to 25 the low memory
complaints group (n = 14). There were no statistically sig-
nificant differences between the high and low memory
complaint groups in demographics, substance abuse his-
tory, or treatment or medication variables. For cognitive
variables, there were no significant differences between
the groups except on the measure of Memory for Persons
Data free recall, on which the respective means for the
high and low groups were 16.7% (SD = 16.7) and 35.7%
(SD = 21.0); (t (27) = 2.66, p = 0.013). As can be seen from
Figure 2, most of the patients classified as high memory
complainers at T2 already had high MCQ scores at T1.
Seventy-one percent of the high memory complainers at
T2 complained of memory problems at T1 matching or
exceeding the MCQ high memory complaints cut-off
score of 26.
Longitudinal changes
In the first working memory task, the Letter-Number
Sequencing, methadone-treated patients' performance
seemed to deteriorate from T1 to T2 as shown by a
decrease in their raw scores. On the other hand, they
seemed to improve in immediate verbal memory per-
formance. Opposite trends were seen in the buprenor-
phine group. However, no significant group by time
interactions emerged.
Discussion
The main finding of this longitudinal study is the persist-
ence of the working memory deficit in OD patients treated
with methadone or buprenorphine along with BZDs. At
T1, the buprenorphine patients were inferior to normal
comparison participants in both working memory tests;
and the methadone patients performed worse than nor-
mal comparison participants at the second working mem-
ory task, the PASAT. At T2, both patient groups were
impaired relative to a normal comparison group on both
working memory tests. The working memory tests used in
this study have both been used also earlier in opioid-
related neuropsychological studies. In an earlier study by
Verdejo-Garcia et al., minimum 15 days abstinent heroin
abusers outperformed methadone-treated OST patients
WMS-III Logical 
Memory, free recall after 
short (30 min) delay 
(T2)
87.1 (14.4) 93 .8 (17.1) 98.3 (14.1) F (2, 38) = 1.28,
p = 0.29
--
Memory for Persons 
Data, free recall after 
short delay (30 min) 
(T1)
92.8 (7.9) 98.2 (6.1) 98.7 (3.1) χ2(2, N = 43) = 
4.48
p = 0.11
--
Memory for Persons 
Data, free recall after 
long delay
(4 – 8 mo) (T2)
22.1 (18.1) 29.8 (23.2) 32.4 (22.1) χ2(2, N = 43) = 
1.54
p = 0.46
--
Memory for Persons 
Data, recognition after 
long delay (4 – 8 mo) 
(T2)
79.6 (10.6) 82.1 (12.9) 81.3 (10.7) F (2, 38) = 0.60
p = 0.55
--
Memory complaints, 
raw score
The Memory Complaint 
Questionnaire (T1)
26.6 (5.7) 26.0 (5.4) 20.4 (2.5) χ2(2, N = 43) = 
11.25
U = 39.0,
p = 0.012, NC < 
M*
-
p = 0.004** U = 40.0, p = 0.008, 
NC < BN **
-
The Memory Complaint 
Questionnaire (T2)
25.6 (3.2) 24.5 (6.7) 20.4 (1.5) χ2 (2, N = 43) = 
14.04
U = 16.5, p < 0.001, 
NC < M***
p = 0.001*** U = 49.0, p = 0.015, 
NC < BN *
Note: PASAT = Paced Auditory Serial Addition Task;
WMS-III = Wechsler Memory Scale-third version.
BN = buprenorphine or buprenorphine/naloxone, M = methadone, NC = Normal comparison.
a = Missing value of one participant was substituted by carry-over value from the first test.
*** = statistically significant at level p < 0.001, ** = statistically significant at level p < 0.01, * = statistically significant at level p < 0.05, ns = non-
significant.
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on our first working memory measure, the Letter-Number
Sequencing [41]. In a study by Mintzer and Stitzer, meth-
adone-treated OST patients performed worse than a well-
matched normal comparison group on a two-back work-
ing memory task closely resembling the PASAT [42]. The
evidence for opioid agonist effects is not, however, unam-
biguous because in both of these studies, the OST patients
had a previous history of using other substances of abuse,
including BZDs. On the other hand, in a study by Sjögren
et al., pain patients treated with pain drugs other than opi-
oids outperformed non-addicted opioid-treated pain
patients on the PASAT [17]. In the same vein, a recent
study showed that the opioid agonist morphine nega-
tively affects working memory performance in healthy
volunteers [16]. Although pure OST drug effects on work-
ing memory seem possible, the effects of OST drugs, alone
or in combination with BZDs, on working memory can
only be reliably examined if OST patients with and with-
out a history of BZD use can be compared.
Our hypothesis of impaired performance in immediate
verbal memory was partially confirmed as both patient
groups were impaired at T1 in the first trial of a list learn-
ing task, the Memory for Persons Data. This finding is in
line with earlier studies showing similar deficits among
methadone patients [9,43]. However, the stability of this
deficit in verbal list learning remains to be studied
because the Memory for Persons Data learning task was
not repeated at T2. Of note here is the study of Gruber et
al. concerning an earlier treatment phase than was inves-
tigated in our study [14]. In their study methadone-
treated patients' verbal list learning performance,
improved between the first testing performed after a mean
of two weeks of OST and the second after two months of
treatment. However, a control group was lacking in their
study. Although alternate test forms were used, practice
effect in repeated verbal memory testing cannot be ruled
out [44]. Thus, the evidence for early improvement of
memory function is not strong.
Buprenorphine patients with concurrent BZD medication
showed inferior list learning during early OST (T1). This
finding is in line with a recent study by Soyka et al. in
which buprenorphine patients without other dependen-
cies were also inferior to normal comparison participants
in verbal learning [45]. In a recent study by Loeber et al.
no significant correlation was found between buprenor-
phine dose and verbal list learning performance [46]. On
the other hand, Lintzeris et al. have reported that
buprenorphine in combination with the BZD diazepam
impairs delayed verbal memory more than buprenor-
phine given alone [19]. In sum, further studies of the pos-
sible "pure" buprenorphine effects or the additive
negative effects of buprenorphine and BZDs on immedi-
ate verbal memory are needed.
Memory consolidation was examined by short- and long-
term retention percentages. No significant group differ-
ences between patient groups and normal comparison
group were observed in any condition. This is surprising
because mu opioid receptor agonists and BZDs are known
to negatively affect memory consolidation [47-50], How-
ever, our study is the first to study memory consolidation
up to late memory consolidation that starts few hours
after event occurrence [34,35]. Further studies are needed
Correlation percentage of the Memory for Persons Data,  delayed recall (T2) scores by group Figure 1
Correlation percentage of the Memory for Persons 
Data, delayed recall (T2) scores by group.
Cumulative percentage of the Memory for Persons Data,  delayed recall (T2) scores by group Figure 2
Cumulative percentage of the Memory for Persons 
Data, delayed recall (T2) scores by group.Substance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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to examine if the observation of no memory consolida-
tion impairment among OD patients is due to develop-
ment of tolerance to negative effects of these drugs. There
is some evidence for tolerance to methadone's long-term
effects on episodic memory [51]. Tolerance for episodic
memory impairing effects of BZDs, in general, are small
[52], but among young individuals development of toler-
ance has been reported [53]. The second possible explana-
tion for no memory consolidation impairment is that
negative effects of opioids given along with BZDs may be
hard to detect without a change in drug status. This means
a change from a relatively highly drugged state to a low or
non-drugged state or reverse. It has been reported that
state change from BZD drug to placebo condition may
negatively affect on memory retrieval in comparison to
continuous BZD condition [54].
Analyses of long-term memory consolidation showed that
among OST patients those with high memory complaints
at T2 performed worse than those with low memory com-
plaints in late memory consolidation assessed by free
recall of the Memory for Persons Data items after a mean
delay of six months. Of note here is the observation that
there were no significant differences between high and
low memory complainers on any background or other
cognitive variables.
Self-rated memory problems were elevated among OD
patients treated along with BZDs at both test points. Thus
the patients feel that in regards to memory function their
quality of life does not improve during the OST. Although
OD patients often have both subjective and objective
memory problems, few studies have addressed the rela-
tionship between subjective and objective memory func-
tion among patients with substance abuse problems
[13,55,56]. In these studies patients' memory complaints
have had small, if any, associations with their objective
memory performance. In our study, though, moderate
relationships were seen between subjective memory com-
plaints and objective memory test performance, especially
in late memory consolidation. Unfortunately, late mem-
ory consolidation deficit is not easily captured by stand-
ard neuropsychological assessment.
Methodological innovations to assess long-term memory
consolidation in clinical settings are needed.
Treatment and policy implications
Working memory function is considered a gateway for
problem solving in new situations, which requires fluid
intelligence and executive function. Thus, when working
memory capacity is low, practical reasoning tends to result
in instant firm decisions that are based on readily availa-
ble salient observations [57,58]. Among OST patients this
may mean that individuals with low working memory
capacity readily associate their negative sentiments with
the common belief that their OST medication is "insuffi-
cient". They may feel overwhelmed if asked to consider
the counterexamples that co-occurrence of medication
and negative sentiments may be coincidental or that neg-
ative drug effects may be short-lived in comparison to the
positive effects that will show up later.
An OST patient who is using BZD medication and who
has working memory impairment may show excellent
memory in one instance and very poor memory in
another. The variability of a patient's performance level in
rehabilitation settings or at work or school may cause con-
fusion in the clinic and the community. To minimize this,
adequate examinations should be performed, and infor-
mation should be provided to the patient and his/her
treatment team more frequently than is currently the case.
The results indicate that memory deficits in OST patients
with current or recent BZD use are rather stable at least
during the first six months of their treatment. It is possible
that this is associated with OST drugs and BZDs given
legally to the OD patients. However, this does not mean
that OST would be harmful for the recovery of OD
patients. OD patients entering OST are, in general, so
stuck in the addiction, that a abstinence oriented treat-
ment program with no opioid or BZD agonists is a realis-
tic alternative only in rare cases [1,4]. Both treatment
alternatives are needed, but OST should be seen as the
mainstream option.
Limitations
Comparing a clinical sample of OST patients who use
BZDs and other psychoactive medications against normal
comparison participants imposes several limitations.
Some of the patients (see Table 2), but none of the com-
parison participants were abusing illicit drugs. This is clear
confounding factor that is difficult to eliminate when
evaluating performances in memory tests. The same
applies to other psychoactive medications that were
legally given to some of the patients but none of the com-
parison participants. Thus, our results cannot be general-
ized to OD patients without psychoactive medications
who have achieved long-term abstinence from any illicit
use of drugs. Psychiatric comorbidity that included Axis I
and Axis II disorders was common among patients and
absent among comparison participants. A recent study by
Prosser et al [59] examined correlates of cognitive func-
tion in a relatively large sample of opioid dependent
patients (n = 56). It was found that personality pathology
accounted for a greater portion of the variance in cognitive
performance than any of the variables of drug use history.
However, the only memory variable included in their
analyses was immediate visual memory.
The mean opioid agonist doses given to our patients
changed between test points, while the mean BZD dosesSubstance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
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and illegal substance abuse remained rather stable. The
methadone dose increased from a mean of 73 mg at T1 to
126 mg at T2. The buprenorphine dose increased from a
mean of 17 mg at T1 to 23 mg at T2. Thus, dose change
and time factors are both affecting the results, and with
our study design, separating these effects is not possible.
The buprenorphine group included both buprenorphine-
only and buprenorphine/naloxone patients. This was par-
tially a practical issue because the majority of buprenor-
phine patients in Finland have been transferred to
buprenorphine-naloxone combination medication. There
is no evidence that sublingual naloxone exhibits opioid
antagonist activity or would interfere with the opioid ago-
nist effects of buprenorphine [26,60]. However, because
there are no studies directly comparing buprenorphine-
only and buprenorphine/naloxone patients, combining
these patients can be considered a limitation of our study.
The list learning task (the Memory for Persons Data) was
not repeated at T2, which poses a limitation for the anal-
yses of immediate verbal memory. Psychoactive drugs,
such as short-acting non-BZDs, neuroleptics, or opioid
withdrawal relievers, were given to both patient groups in
order to alleviate opioid withdrawal symptoms or to treat
psychiatric comorbidity. The possible interactions of OST
medications with these medications warrant further stud-
ies with larger sample sizes. Recent-month drug screens
were considered important because it is known that long-
term use of benzodiazepines or cannabis may have a neg-
ative impact on cognitive function even weeks after cessa-
tion of use [18,61]. However, our data cannot determine
the precise doses used during the recent month, nor does
the data cover full time span of the follow-up. Thus, the
results do not reflect "pure" drug effects of OST drugs and
BZDs. On the other hand, no major differences between
the substance abuse profiles of methadone and buprenor-
phine patients were seen. OD patients may differ from the
general population already in their premorbid cognitive
functioning [62]. Screening for premorbid conduct or
attention deficit disorder could possibly reveal interac-
tions with current cognitive functions among OST
patients [63,64]. However, retrospective assessment of
these has low reliability in the absence of longitudinal
records [65]; therefore, these assessments were not done
in our study. Finally, our sample size was relatively small,
and therefore type 2 errors cannot be excluded.
Conclusion
OD patients treated with methadone or buprenorphine
along with BZDs showed substantial deficits in working
memory both during beginning of the treatment, and
after six months of treatment. Given the previously stated
limitations of this study, we conclude that OD patients
taking opioid agonist drugs and BZDs score worse than
normal comparison persons in tests of memory during
first six months of their OST. Thus, it is possible that the
working memory deficit observed among these patients
might be relatively permanent. An immediate verbal
memory deficit may also be seen among them. Surpris-
ingly, there were no significant memory consolidation dif-
ferences between the patient groups and normal
comparison group. On the other hand, OST patients
reported subjective memory problems that were associ-
ated with poor late memory consolidation. This has obvi-
ous functional relevance for the patients. Therefore, we
propose that the relationship between subjective and
objective memory function should be taken into account
in longitudinal studies of substance abuse treatment and
clinical practice.
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